F. Bosch

Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial.

H. Kitchener, M. Lehtinen, X. Castellsagué, 2012, The Lancet. Oncology.

Risk of Newly Detected Infections and Cervical Abnormalities in Women Seropositive for Naturally Acquired Human Papillomavirus Type 16/18 Antibodies: Analysis of the Control Arm of PATRICIA

C. Wheeler, H. Kitchener, M. Lehtinen, 2014, The Journal of infectious diseases.

Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial.

C. Wheeler, H. Kitchener, M. Lehtinen, 2012, The Lancet. Oncology.

Human papillomavirus (HPV) and related cancers in the Global Alliance for Vaccines and Immunization (GAVI) countries. A WHO/ICO HPV Information Centre Report.

L. Bruni, S. de Sanjosé, X. Castellsagué, 2012, Vaccine.

Recommendations for cervical cancer prevention in Central and Eastern Europe and Central Asia.

M. Poljak, K. Seme, F. Bray, 2013, Vaccine.

Recommendations for cervical cancer prevention in Asia Pacific.

J. Cuzick, D. Parkin, Y. Qiao, 2008, Vaccine.

Human Papillomavirus (HPV) infection in pregnant women and mother-to-child transmission of genital HPV genotypes: a prospective study in Spain

S. de Sanjosé, X. Castellsagué, A. Goncé, 2009, BMC infectious diseases.